Navigation Links
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
Date:11/8/2010

children and adults taking TNF blockers, including REMICADE, the chances of getting lymphoma or other cancers may increase.

You should discuss any concerns about your health and medical care with your doctor.

What should I tell my doctor before I take REMICADE?

You should let your doctor know if you have or ever had any of the following:

  • Tuberculosis (TB) or have been near someone who has TB. Your doctor will check you for TB with a skin test. If you have latent (inactive) TB, you will begin TB treatment before you start REMICADE.
  • Lived in a region where certain fungal infections like histoplasmosis or coccidioidomycosis are common.
  • Infections that keep coming back, have diabetes or an immune system problem.
  • Any type of cancer or a risk factor for developing cancer, for example, chronic obstructive pulmonary disease (COPD) or had phototherapy for psoriasis.
  • Heart failure or any heart condition. Many people with heart failure should not take REMICADE.
  • Hepatitis B virus (HBV) infection or think you may be a carrier of HBV.
  • Nervous system disorders (like multiple sclerosis or Guillain-Barre syndrome).

Also tell your doctor about any medications you are taking, including vaccines or Kineret (anakinra), and if you are pregnant, plan to become pregnant or are nursing. Adults and children should not receive a live vaccine while taking REMICADE.

What should I watch for and talk to my doctor about before or while taking REMICADE?

The following serious (sometimes fatal) side effects have been reported in people taking REMICADE.

You should tell your doctor right away if you have any of the signs listed below:

  • Infections (like TB, blood infections, pneumonia)—fever, tiredness, cough, flu, or warm, red or painful skin or any open sores. REMICADE can make you more likely
    '/>"/>

SOURCE Centocor Ortho Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
2. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
3. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
4. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
5. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... Conn. , Oct. 22, 2014  Recently published ... have bolstered the already substantial database of evidence. This ... adoption of Stretta therapy for sufferers of ... clinical evidence supporting Stretta therapy as a ... policies that make Stretta therapy available to nearly 50 ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... 1 The boards of directors for ... Care announced today the appointment of,Thomas Lescault ... In Arizona, SCAN offers a health plan ... long-term care services to,individuals enrolled in the ...
... Corporation,(Nasdaq: SMTS ) announced today that its Board ... an additional $15 million of its common,shares (for a ... may be,made from time to time in the open ... amount of, and purposes for, any,purchases will be determined ...
... the first time, researchers have demonstrated that the administration ... or H2S the molecule that gives rotten eggs ... blood loss in rats. , Cell biologist Mark B. ... of Fred Hutchinson Cancer Research Center, in collaboration with ...
... researchers say , , TUESDAY, July 1 (HealthDay News) -- ... by examining characteristics of the first two cases of ... analysis of data on more than 18,200 Dutch patients ... concluded there,s a 56 percent chance of a large ...
... Services,Inc., has been sold to Assurance Investment Partners (AIP). ... in Kentucky, Arison has six,offices across Kentucky and sells ... The company will continue to operate under the ... will be employed by AIP. Paul,Anderson, who served as ...
... the insurer on the annual listing for the ... ... Today Black Enterprise magazine,applauded Aflac,s outstanding achievements in workplace diversity ... Diversity listing.,This recognition highlights the well-branded insurer,s remarkable minority,representation in ...
Cached Medicine News:Health News:SCAN Health Plan Arizona and SCAN Long Term Care Appoints Thomas Lescault President of Arizona Operations 2Health News:Somanetics Announces Share Repurchase Program Increased By $15 Million 2Health News:'Hibernation-on-demand' drug significantly improves survival after extreme blood loss 2Health News:'Hibernation-on-demand' drug significantly improves survival after extreme blood loss 3Health News:TB Outbreaks May Be Predicted by First 2 Cases 2Health News:Assurance Investment Partners Purchases Arison Insurance Services from Anthem Blue Cross and Blue Shield 2Health News:Aflac Named as a Top Company for Diversity by Black Enterprise Magazine 2Health News:Aflac Named as a Top Company for Diversity by Black Enterprise Magazine 3
... The Dual Media Set, different from ... Broth (LB) or other specially prepared medium, ... OVEREXPRESSION BROTH (OB). For cell expansion, E. ... the production of the recombinant protein is ...
...
0.3% Beef extract, 0.5% Peptone, 0.5 % Lactose....
... controls the temperature at your lab bench. This ... to 99 C*, with the "plus" being a ... C. The thermoblocks for 0.2 ml**, 0.5 ml, ... a high degree of flexibility for a multitude ...
Medicine Products: